Get the Stockscreener App
20.02
4.87%
0.93
Braveheart Bio, Inc. Common Stock stock is traded at $20.02, with a volume of 254.92K.
It is up +4.87% in the last 24 hours and down -30.75% over the past month.
See More
Previous Close:
$19.09
Open:
$18.91
24h Volume:
254.92K
Relative Volume:
0.45
Market Cap:
$1.80B
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
-5.88%
1M Performance:
-30.75%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$17.86
$22.02
52-Week Range:
$17.86
$32.00
Braveheart Bio, Inc. Common Stock Stock (BRVE) Company Profile
Name
Braveheart Bio, Inc. Common Stock
Sector
Industry
Phone
-
Address
-
Compare BRVE vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRVE
Braveheart Bio, Inc. Common Stock
|
20.02 | 1.80B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Braveheart Bio, Inc. Common Stock Stock (BRVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-26 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-26 | Initiated | Goldman | Buy |
| Aug-31-26 | Initiated | Jefferies | Buy |
| Aug-31-26 | Initiated | Stifel | Buy |
| Aug-31-26 | Initiated | TD Cowen | Buy |
Braveheart Bio, Inc. Common Stock Stock (BRVE) Latest News
Braveheart Bio, Inc. Common Stock (NASDAQ: BRVE) Stock Price, News & Analysis - Kalkine
Braveheart Bio, Inc. (NASDAQ:BRVE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Braveheart Bio, Inc. Common Stock (NASDAQ: BRVE) Stock Price, News & Analysis - kalkine.ca
OrbiMed's stake in Braveheart Bio (BRVE) falls without selling shares - Stock Titan
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
AH Bio Fund IV Discloses Investment at Braveheart Bio with 11.4% Stake - TradingView
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success? - The Motley Fool
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors? - The Motley Fool
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors? - The Motley Fool
Braveheart Bio, Inc. Common Stock (BRVE) Stock Price Today: $27.43 - Gotrade
Braveheart Bio Announces Closing of Upsized Initial Public - GlobeNewswire
Braveheart Bio raises $439.9M in upsized Nasdaq IPO - Investing.com
Braveheart Bio closes $439.9 million IPO on Nasdaq - Investing.com
Braveheart Bio Insider Bought Shares Worth $499,986, According to a Recent SEC Filing - Yahoo Finance
Heart drug developer Braveheart Bio surges on public debut after upsized IPO - Seeking Alpha
Braveheart Bio Announces Pricing of Upsized Initial Public Offering - The Manila Times
Braveheart Bio Shares Rise After Market Debut - Yahoo Finance
Braveheart Bio Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Braveheart Bio shares surge 68% in New York trading debut - Investing.com
Braveheart Bio (Nasdaq:BRVE)Stock Analysis - Simply Wall Street
Braveheart Bio, Inc. (BRVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Braveheart Bio Expects Nasdaq Debut Aug. 6 After $18 IPO - Stock Titan
Braveheart Bio prices IPO at $18 per share, raises $382.5M - Investing.com
Braveheart Bio, Inc. IPO Analysis: Financial Outlook, Broker Coverage and Listing Prospects - Minichart
Funding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s - Pharmaceutical Executive
Braveheart Bio Readies $300 Million IPO Plan (BRVE) - Seeking Alpha
Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs - Seeking Alpha
Braveheart Bio seeks $318.8M in IPO for heart drug - Investing.com
Braveheart Bio, Inc. Common Stock Stock (BRVE) Financials Data
There is no financial data for Braveheart Bio, Inc. Common Stock (BRVE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Braveheart Bio, Inc. Common Stock Stock (BRVE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chimovits Erez | Director |
Aug 07 '26 |
Buy |
18.00 |
1,940,000 |
34,920,000 |
11,901,826 |
| ORBIMED ADVISORS LLC | Director |
Aug 07 '26 |
Buy |
18.00 |
1,940,000 |
34,920,000 |
11,901,826 |
| Forbion Growth Opportunities F | 10% Owner |
Aug 07 '26 |
Buy |
18.00 |
1,920,000 |
34,560,000 |
11,640,546 |
| Forbion Growth Opportunities F | 10% Owner |
Aug 07 '26 |
Buy |
18.00 |
1,680,000 |
30,240,000 |
10,185,478 |
| Rickey James Paul | Chief Financial Officer |
Aug 07 '26 |
Buy |
18.00 |
27,777 |
499,986 |
520,927 |
| Viehbacher Christopher | Director |
Aug 07 '26 |
Buy |
18.00 |
83,333 |
1,499,994 |
609,519 |
| Malek David I | Director |
Aug 07 '26 |
Buy |
18.00 |
4,166 |
74,988 |
533,845 |
| Anderson Michele A. | Chief Development Officer |
Aug 07 '26 |
Buy |
18.00 |
1,111 |
19,998 |
332,161 |
| Murdoch Travis | CEO and President |
Aug 07 '26 |
Buy |
18.00 |
83,333 |
1,499,994 |
2,940,670 |
| Lubner David Charles | Director |
Aug 07 '26 |
Buy |
18.00 |
55,555 |
999,990 |
55,555 |
0.41%
3.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):